Utidelone Capsule

DRUG4 trials

Conditions

Advanced Breast CancerAdvanced Solid TumorBile Duct CancerGastric Cancer Adenocarcinoma MetastaticGastric or Gastroesophageal Junction AdenocarcinomaOvarian Cancer

Phase 1

Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors

NCT05681000

Biostar Pharma, Inc.Advanced Solid Tumor

Start: 2023-06-09End: 2024-12-31Target: 28Updated: 2023-11-09

Phase 2

Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors

Not yet recruitingNCT06730581

Beijing Biostar Pharmaceuticals Co., Ltd.Bile Duct Cancer, Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer

Start: 2024-12-01End: 2026-12-31Target: 100Updated: 2024-12-12

Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

RecruitingNCT06841679

Beijing Biostar Pharmaceuticals Co., Ltd.Gastric or Gastroesophageal Junction Adenocarcinoma

Start: 2025-08-28End: 2030-09-01Target: 778Updated: 2025-11-25

Phase 3

Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer

Not yet recruitingNCT07684456

Beijing Biostar Pharmaceuticals Co., Ltd.Advanced Breast Cancer

Start: 2026-08-01End: 2029-03-01Target: 308Updated: 2026-07-06

Related Papers

Efficacy and safety results of a multi-center phase I study of utidelone capsule, a novel oral microtubule inhibitor, in advanced solid tumor patients.

Journal of Clinical Oncology2025-05-28

A novel oral microtubule inhibitor utidelone capsule (UTD2): A phase 1 clinical study to assess the tolerability, safety, and efficacy in advanced solid tumors.